VX14-661-108: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for th
|Effective start/end date||3/20/15 → 1/1/18|
- Vertex Pharmaceuticals Incorporated
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.